Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGNAL-AA: Bempikibart in Severe Alopecia Areata
NCT06018428Phase 2Active, not recruiting
- Sponsor
- Q32 Bio
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of bempikibart in alopecia areata (3 arms), sponsored by Q32 Bio. Primary endpoint: Severity of Alopecia Tool Score at 36 weeks. Started Sep 2023; status: active, not recruiting.
02
Drugs
bempikibart
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT06018428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06018428.